ANZCTR search results

This trial aims to evaluate the feasibility and acceptability of a 10-week, individualised exercise-based wellbeing program designed for students with disability at an Australian university. Conducted through a mixed-methods pilot study, the program will be delivered by Accreditted Exercise Physiologists both online via Zoom and on-campus, collaborating closely with other student support services. The program being investigated is funded by the administrative division of the university and will assess various aspects such as program retention, adherence, resource requirements, and participant satisfaction. It is expected to improve participants' quality of life, psychosocial health, health behaviors, and physical health measures. The study will involve 20 participants, recruited through the university's accessibility and disability services, and will be conducted from July to November 2024.

Our study investigates how fibre is broken down by the microbiota of patients who have undergone ileoanal pouch surgery, a procedure where the colon is removed and the small intestine is reshaped to act as a new storage area for waste. We aim to understand how fibre fermentation varies among these patients and compare it to individuals with a healthy colon. This research is crucial because dietary fibre, known for its beneficial effects on gut function, may behave differently in the altered digestive anatomy of pouch patients, potentially influencing inflammation and symptom management. By clarifying these relationships, we hope to provide tailored dietary recommendations that can optimise the well-being and quality of life for patients with an ileoanal pouch.

This study aims to assess whether 5% 5-FU followed by CICAPLAST Baume B5+ on a twice daily application to the face or arms/hands will result in better tolerance and compliance as compared to 5-FU alone Who is it for? You may be eligible for this study if you are a male or female age 18 or older been prescribed a field therapy with Topical 5% Fluorouracil for actinic keratoses or in chemoprevention of SCC on the face or hands and/or arms. Study details Participants will be recruited from the Princess Alexandra hospital by treating trial physician during a clinical consultation at the dermatology clinic and followed up during weekly consultations for 4 weeks in clinic or via telehealth. They will receive either only Topical 5% Fluorouracil or Topical 5% Fluorouracil followed by Cicaplast Baume B5+ on a twice daily application to the face or hands and/or arms for 4 weeks. At the end of the study, participant's skin condition and adherence to the intervention will be assessed. It is hoped that the findings from this study will help doctors in the future treat patients being prescribed 5-FU for precancerous AK.

Psilocybin is proposed to act via a loosening of cognitive control processes thereby rectifying deeply engrained patterns of thought and behaviour to promote cognitive flexibility. There is also evidence that psychedelics (psilocybin & LSD) alter dopaminergic reward signalling in healthy participants, but whether or not this is associated with responses to food choice or food reward is unknown. This project with use brain imaging techniques to investigate the brain networks that integrate information about the nutritional state of the body (e.g., hunger, satiety) with decision-making systems important to food choice and how they are altered by psilocybin. To do this, we will acquire brain scans of healthy adults before and after they have been administered a single dose of psilocybin, while they are completing an in-scan food choice task using a custom designed liquid food delivery apparatus (a "gustometer"). This information is critical to inform the therapeutic application of psilocybin in eating disorders such as anorexia nervosa, in which patients experience aberrant food reward processing that contributes to their disorder maintenance and relapse. Clinical trials in this patient population are already underway, underscoring the important of obtaining this critical information in a timely manner.

This study will evaluate the role of FAPI-46 (Fibroblast activation protein inhibitor) PET (positron emission tomography) imaging in prognosis and response to immunotherapy in metastatic cancers Who is it for? You may be eligible to join this study if you are aged 18 years and above, have histologically confirmed metastatic head and neck squamous cell carcinoma, hepatocellular carcinomas, mesothelioma, non-small cell lung cancers and planned for immunotherapy containing regimen only. Study details All participants in this study will have FAPI-46 PET imaging performed before immunotherapy treatment. We will also assess FAP expression via immunohistochemistry on the available tissue samples that were already taken for diagnosis. Correlation of FAP expression in tumour samples via immunohistochemistry and FAP expression on imaging will be assessed. This research will help provide insight in the role of FAPI-46 PET scan and FAP in predicting prognosis and could be a stepping stone for future applications in potential targeted treatment and theranostics.

The GenI-AIRSPACE trial aims to understand how genetic testing results influence decisions for people with favourable intermediate-risk prostate cancer. We want to see if these test results can help us safely recommend active surveillance for those with lower genetic risk or suggest treatment if their cancer is more likely to progress. Who is it for? You may be eligible for this study if you are aged 18 years or older with a histological diagnosis of prostate adenocarcinoma with no evidence of metastatic disease, and your treating doctor has recommended ‘active surveillance’, as an alternative to having surgery or radiation therapy now. Almost half of the new prostate cancers diagnosed each year in Australia are referred to as being of ‘favourable intermediate risk,’. This classification indicates that progression to treatments such as surgery or radiation can, in some circumstances, be deferred and the cancer safely monitored over time. This classification is based on results from routine tests, including biopsy results, diagnostic tests like bone or CT scans, and prostate specific antigen or PSA blood tests. Study details Eligible participants will be randomly assigned to one of two groups: the standard of care treatment group which continue in usual care with their treating doctor, or the genomically informed group who will undergo genetic tests to be classified as either high risk or low risk for their cancer to progress. To conduct the genetic tests, the study team will request access to tissue samples from previous prostate cancer biopsies and a fresh10mL blood sample (about 2 teaspoons) will be collected. The results of these tests will be provided with no explicit treatment recommendation. Instead, the information will be provided to both the participant and the treating doctor, and any treatment decisions will be made through shared decision-making. This is a randomised trial, and each participant will have an equal chance (50%) of being allocated into each group. The group assignment will be decided by a computer, so neither the participant nor the doctor can choose the group Both groups will answer questions about their quality of life at the start of the trial, then every six months for a year, and then once a year after that. They will be followed for up to ten years to see if they start treatment for prostate cancer, whether the disease has progressed, and if it has spread. It is hoped that findings from this study will help determine the utility of genomic screening in individualising treatment pathways for people diagnosed with intermediate-risk prostate cancer, and help lessen the number of people who get intense treatment, without hurting their long-term health outcomes.

This multi-method evaluation will evaluate the feasibility, acceptability, and effectiveness of a caregiver wellbeing program delivered by CaFHS in South Australia. The caregiver wellbeing program will deliver evidence-informed caregiver wellbeing psychoeducation into these routine services. Our evaluation aims to determine whether the caregiver wellbeing program is feasible and acceptable to deliver within these routine services and whether it is effective in improving the wellbeing of caregivers. To achieve our aims, we will conduct pre- and post- program surveys and focus groups with caregivers who participated in the program, and staff who were involved in implementing or delivering the program. To support and evaluate a future statewide roll out, this study will also evaluate the feasibility of conducting a definitive trial.

Decompensated cirrhosis is associated with high morbidity and mortality as well as high resource utilisation and healthcare costs. This study aims to provide evidence for a novel intervention to reduce hospitalisation in this vulnerable cohort. We hypothesise that continuous terlipressin infusion will be more effective than weekly albumin infusions in the prevention of decompensating liver events in cirrhosis

This project aims to investigate resident and family engagement in communicating about psychotropic medicines by developing and testing creative strategies in aged care facilities. Psychotropic medicines affect the mind, emotions and behaviour of individuals. The project will involve the conduct of interviews and observations, which will help to inform the conduct of co-design panels. Strategies developed from co-design panels will be evaluated in a feasibility and acceptability trial. Knowledge dissemination of the results will occur with audio scenario interviews, development of infographics and workshops at the aged care sites.

The aim of the study is to develop and test tailored co-designed strategies that are agreed upon between hospitalised older people, their families and health professionals in managing medications as patients move across transitions of care. Strategies developed from feedback events and co-design group workshops, will be tested in a feasibility and acceptability trial. The work will inform the future development and testing of a randomised controlled trial of co-designed engagement strategies.